Biocentury Emerging Company Profile - Accession: precisely targeted oncolytic viruses

Bent Jakobsen’s newest biotech is replacing the virus’ natural tropisms with an integrin-based cancer targeting mechanism - read the article by Richard Guy, Biopharma Analyst, here >

bc-accession-precisely-targeted-oncolytic-viruses

.pdf

Download PDF • 234KB